Medicare, Medicaid to cover advanced cancer genetic tests starting 2027

What it does

This bill requires Medicare, Medicaid, and CHIP to cover advanced cancer diagnostic tests (genetic sequencing, microarray analysis, and similar tests) starting January 1, 2027, with Medicare paying 80% of the cost after the patient meets their deductible. It also directs the federal government to educate doctors and the public about genetic testing for cancer. The bill is named after Finn Sawyer, suggesting a personal or advocacy origin.

Why we flagged it

The bill's core mechanism is straightforward: it mandates federal health program coverage of advanced cancer diagnostic tests. The legislative vehicle is a coverage expansion, not a tax provision, subsidy, or deregulation. The naming after Finn Sawyer suggests advocacy or personal origin but does not change the bill's functional character.

What the text implies

• The bill does not cap or limit the cost of these tests to Medicare/Medicaid; payment is set at 80% of the lesser of actual charge or the clinical lab rate, meaning high-cost tests will still generate substantial federal outlays.
• Frequency limits (once at diagnosis, once at recurrence, as needed for treatment planning) are defined by the bill but may be subject to interpretation disputes between providers and payers.
• The education and awareness program (Section 3) is unfunded and open-ended; no appropriation is specified, so implementation depends on HHS discretion and available budget.
• Medicaid coverage does not take effect until January 1, 2027, creating a 2-year lag; state plans have additional time to comply if state legislation is required, potentially delaying access in some states.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens with cancer gain access to advanced diagnostic tests that can guide treatment decisions, with Medicare/Medicaid covering 80% of costs and no deductible. The public bears the cost through federal health programs, but the benefit—earlier detection and better treatment planning—is a genuine public health gain.

Who stands to gain

• clinical laboratories offering genetic sequencing and microarray analysis
• genetic testing companies and diagnostic labs
• oncology practices offering molecular diagnostics

Named in the bill

Medicare, Medicaid, CHIP (Children's Health Insurance Program), Social Security Act, HHS (Department of Health and Human Services), National Human Genome Research Institute, clinical laboratories, genetic counselors

Where it stands

13 cosponsors: 11 Democrats, 2 Republicans.

• Feb 26, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 26, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.